Financial reports
ARS
2023 FY
Annual report to shareholders
19 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
27 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
14 Dec 23
8-K
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
8 Nov 23
8-K
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
31 Oct 23
8-K
Cost Associated with Exit or Disposal Activities
19 Oct 23
8-K
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Entry into a Material Definitive Agreement
10 May 23
8-K
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
10 May 23
Registration and prospectus
S-3ASR
Automatic shelf registration
27 Feb 24
S-8
Registration of securities for employees
27 Feb 24
424B5
Prospectus supplement for primary offering
10 May 23
S-8
Registration of securities for employees
28 Feb 23
S-8
Registration of securities for employees
28 Feb 22
424B5
Prospectus supplement for primary offering
7 Jul 21
S-3ASR
Automatic shelf registration
10 Jun 21
424B5
Prospectus supplement for primary offering
1 Apr 21
424B7
Prospectus with selling stockholder info
1 Apr 21
424B7
Prospectus with selling stockholder info
1 Apr 21
Proxies
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
Other
UPLOAD
Letter from SEC
12 Oct 23
CORRESP
Correspondence with SEC
20 Sep 23
UPLOAD
Letter from SEC
22 Aug 23
CORRESP
Correspondence with SEC
9 Aug 23
UPLOAD
Letter from SEC
20 Jul 23
EFFECT
Notice of effectiveness
1 Oct 20
CORRESP
Correspondence with SEC
28 Sep 20
CORRESP
Correspondence with SEC
28 Sep 20
UPLOAD
Letter from SEC
23 Sep 20
EFFECT
Notice of effectiveness
6 Feb 20
Ownership
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Amy Simon
3 Apr 24
4
Christine Bellon
3 Apr 24
4
Terry-Ann Burrell
3 Apr 24
4
John M. Evans
3 Apr 24
4
Giuseppe Ciaramella
3 Apr 24